SGLT2 Inhibitors and Cardiorenal Outcomes in the February 2019 issue of @KidneyNews
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 kidneynews.org/kidney-news/is…
EMPA-REG: Empagliflozin, CV outcomes and mortality in Type 2 Diabetes ca. 2015 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
CV and Renal Outcomes With Canagliflozin According to Baseline Kidney Function ca. 2018 from @CircAHA
#VisualAbstract by @brendonneuen
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 ahajournals.org/doi/pdf/10.116…
Effect of SGLT2 inhibitors on CV, renal and safety outcomes in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis ca. 2019
#VisualAbstract by @brendonneuen
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 ncbi.nlm.nih.gov/m/pubmed/30697…
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials ca. 2018 from @TheLancet
#VisualAbstract by @divyaa24
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 ncbi.nlm.nih.gov/m/pubmed/29937…
MT @Nephro_Sparks CREDENCE: Canagliflozin reduced the risk of the primary outcome of ESKD, doubling of SCr, or renal or CV death by 30%‼️
#ISNWCN 🇦🇺🦘 #Nephpearls
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM
#VisualAbstract by @brendonneuen
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #NephJC
#VisualAbstract by @brendonneuen
#ISNWCN 🇦🇺🦘 #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
CREDENCE: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Study Rationale, Design, and Baseline Characteristics ca. 2017 from @AmJNephrol #Nephpearls
👉🏼 karger.com/Article/Pdf/48…
Ongoing trials of SGLT2 Inhibitors of interest to the Nephrology Community ca. 2019
Table by @drlovygaur #Nephpearls #NephJC
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #Nephpearls
👉🏼 nejm.org/doi/pdf/10.105…
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD ca. 2019 from @AJKDonline #Nephpearls
👉🏼 ajkd.org/article/S0272-…
Class effects of SGLT2 inhibitors on cardiorenal outcomes ca. 2019 #Cardiorenal #Nephpearls
👉🏼 cardiab.biomedcentral.com/articles/10.11…
SGLT2 Inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin) are recommended to lower risk of heart failure hospitalization‼️
#ESCcongress 🇫🇷 #Nephpearls #Cardiorenal
👉🏼 escardio.org/Guidelines/Cli…
SGLT2 Inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin) are recommended to lower risk of heart failure hospitalization‼️
#ESCcongress 🇫🇷 #Nephpearls #Cardiorenal
👉🏼 escardio.org/Guidelines/Cli…
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis ca. 2019 from @TheLancetEndo @brendonneuen @jardine_meg @VladoPerkovic #Nephpearls
👉🏼 thelancet.com/journals/landi…
Diabetes and Kidney Disease: SGLT2 Inhibitors by @ChristosArgyrop in the August 2019 issue of @KidneyNews #Nephpearls
👉🏼 asn-online.org/publications/k…
Emerging glucose-lowering therapies ca. 2019 from @DrMattGB @bmj_latest #Nephpearls
👉🏼 ncbi.nlm.nih.gov/m/pubmed/31551…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.